Stockscreener 앱 받기
132.56
0.62%
0.82
시간 외 거래:
132.56
전일 마감가:
$131.74
열려 있는:
$131.93
하루 거래량:
1.13M
Relative Volume:
1.02
시가총액:
$13.30B
수익:
$2.86B
순이익/손실:
$478.60M
주가수익비율:
28.40
EPS:
4.6676
순현금흐름:
$748.70M
1주 성능:
+1.09%
1개월 성능:
+0.23%
6개월 성능:
-3.24%
1년 성능:
+23.89%
1일 변동 폭
$130.25
$133.40
1주일 범위
$128.02
$133.99
52주 변동 폭
$84.23
$160.18
뉴로크린 바이오사이언시스 Stock (NBIX) Company Profile
명칭
Neurocrine Biosciences Inc
전화
(858) 617-7600
주소
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
132.56 | 13.22B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
18.77 | 58.51B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
117.29 | 49.90B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.97 | 44.64B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
30.25 | 35.08B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
570.27 | 25.99B | 3.18B | 1.33B | 1.04B | 27.90 |
뉴로크린 바이오사이언시스 Stock (NBIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 개시 | Citigroup | Buy |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2025-04-15 | 업그레이드 | Needham | Hold → Buy |
| 2025-04-14 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-08-29 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 재개 | Citigroup | Neutral |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 재확인 | Mizuho | Neutral |
| 2023-07-24 | 업그레이드 | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | 업그레이드 | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2023-03-30 | 업그레이드 | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-02-03 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-09-26 | 개시 | Wells Fargo | Equal Weight |
| 2022-06-06 | 재개 | Jefferies | Buy |
| 2022-03-03 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-01-18 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 개시 | BMO Capital Markets | Underperform |
| 2021-11-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-10-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 재개 | Needham | Hold |
| 2021-08-06 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 재개 | Goldman | Neutral |
| 2021-05-06 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 개시 | Raymond James | Outperform |
| 2020-09-30 | 개시 | The Benchmark Company | Hold |
| 2020-08-04 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-06-29 | 다운그레이드 | Goldman | Buy → Neutral |
| 2020-06-09 | 개시 | Wedbush | Outperform |
| 2020-03-06 | 개시 | Citigroup | Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-24 | 개시 | William Blair | Outperform |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-02-05 | 재확인 | H.C. Wainwright | Buy |
| 2019-12-13 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-05 | 개시 | Guggenheim | Neutral |
| 2019-05-21 | 개시 | Credit Suisse | Outperform |
| 2019-04-22 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-02-06 | 재확인 | BofA/Merrill | Buy |
| 2019-01-23 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 개시 | Goldman | Buy |
| 2018-11-21 | 개시 | Canaccord Genuity | Buy |
모두보기
뉴로크린 바이오사이언시스 주식(NBIX)의 최신 뉴스
What Neurocrine Biosciences (NBIX)'s New Senior TD Data and Guidelines Could Mean For Shareholders - simplywall.st
NBIX Technical Analysis & Stock Price Forecast - intellectia.ai
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Neurocrine Biosciences Inc (NBIX) Shares Up 3.15% on Mar 31 - GuruFocus
Responsive Playbooks and the NBIX Inflection - Stock Traders Daily
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN
Neurocrine Biosciences Inc (NBIX) Shares Down 3.14% on Mar 30 - GuruFocus
NBIX SEC FilingsNeurocrine Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Neurocrine Biosciences Stock: A Leader in Neurological and Endocrine Therapies with Strong US Market - AD HOC NEWS
Wealth Enhancement Advisory Services LLC Boosts Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Free cash flow per share of Neurocrine Biosciences, Inc. – DUS:NB3 - TradingView
SG Americas Securities LLC Buys 119,339 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Nordea Investment Management AB Increases Stake in Neurocrine Biosciences, Inc. $NBIX - marketbeat.com
Assenagon Asset Management S.A. Has $11.35 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX - marketbeat.com
[SCHEDULE 13G/A] NEUROCRINE BIOSCIENCES INC Amended Passive Investment Disclosure - stocktitan.net
Neurocrine (NASDAQ:NBIX) Expands Clinical Strategy As Nasdaq Futures Shift - Kalkine Media
Tudor Investment Corp ET AL Buys 23,893 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - chartmill.com
Is Geriatric-Focused INGREZZA Data Quietly Reframing Neurocrine Biosciences' Neurology Leadership Narrative (NBIX)? - Yahoo Finance
Neurocrine Biosciences Updates Tardive Dyskinesia Care And Valuation Story - simplywall.st
Neurocrine presents tardive dyskinesia treatment guidance for elderly - StreetInsider
Neurocrine Biosciences Presents First Expert Consensus Recommendations for Tardive Dyskinesia in Long-Term Care Settings - PR Newswire
Neurocrine Biosciences Inc (NBIX) Shares Up 3.53% on Mar 25 - GuruFocus
Earnings Miss: Why is Neurocrine Biosciences Inc stock going upProfit Target & Consistent Growth Equity Picks - baoquankhu1.vn
Shorts Report: Does Neurocrine Biosciences Inc have pricing powerTrend Reversal & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Strong Growth and Technical Setup - chartmill.com
Truist lowers Neurocrine Biosciences, Inc.’s (NBIX) PT following 2026 outlook update - MSN
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Neurocrine Biosciences, Inc.Common Stock (NQ: NBIX - FinancialContent
CIBC Private Wealth Group Boosts Neurocrine Biosciences Stock Holdings - National Today
CIBC Private Wealth Group LLC Grows Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assessing Neurocrine Biosciences (NBIX) Valuation As Shares Soften Despite Growing Revenue And Net Income - Sahm
Block Trades: Can Neurocrine Biosciences Inc be recession proofProfit Target & Long Hold Capital Preservation Plans - baoquankhu1.vn
Hedge Fund Bets: Can Neurocrine Biosciences Inc maintain its current growth rateWall Street Watch & Safe Entry Trade Signal Reports - baoquankhu1.vn
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Hudson Bay Capital Management LP - marketbeat.com
If You Invested $1,000 in Neurocrine Biosciences Inc (NBIX) - stocktitan.net
Neurocrine Biosciences Maps 2026 Execution, “Data-Rich” 2027; Ingrezza Guides $2.7B–$2.8B - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Case as a Quality Value Stock - ChartMill
Eric Topol boards Flagship as advisor—Chutes & Ladders - fiercebiotech.com
Understanding the Setup: (NBIX) and Scalable Risk - Stock Traders Daily
Wolfe Research initiates coverage of Neurocrine Biosciences (NBIX) with outperform recommendation - MSN
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Neurocrine Biosciences promotes Andrew Ratz to operations chief By Investing.com - Investing.com South Africa
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Tec - GuruFocus
Neurocrine at Stifel CNS Forum: Growth and Strategic Focus - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel 2026 Virtual CNS Forum, Mar-17-2026 04 - marketscreener.com
Neurocrine Biosciences (NBIX) CTO Ratz reports initial stock and option grants - Stock Titan
Neurocrine Biosciences promotes Andrew Ratz to operations chief - Investing.com
Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer - StreetInsider
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer - StreetInsider
뉴로크린 바이오사이언시스 (NBIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
뉴로크린 바이오사이언시스 주식 (NBIX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,133 |
0 |
39,230 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
3,352 |
0 |
7,969 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
1,600 |
0 |
6,313 |
| Gano Kyle | Chief Executive Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,807 |
0 |
147,610 |
| Gano Kyle | Chief Executive Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
4,907 |
0 |
146,661 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
5,407 |
0 |
21,066 |
| Onyia Jude | Chief Scientific Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,560 |
0 |
18,537 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,044 |
0 |
56,664 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,005 |
0 |
54,760 |
| Cooke Julie | Chief Human Resources Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
2,911 |
0 |
30,395 |
3.38%
0.89%
자본화:
|
볼륨(24시간):